Mural Oncology’s Post

As you progress your studies, you can work around the cancer immunity cycle with our comprehensive capabilities across platforms under one roof, designed to support immuno-oncology (IO) research. Download our free resources to learn more. ⬇️ 📄White Paper: When and How to Use Tumor Organoids in Drug Discovery https://hubs.la/Q02YmX_60 📄Application Note: In Vitro and Ex Vivo Immuno-Oncology Drug Discovery https://hubs.la/Q02YmXpL0 See how your IO studies can benefit from our cost-effective models: https://hubs.la/Q02YmYJM0

Multi-drug combination screening studies along with novel high content technologies are being used to identify promising multi-drug combination regimens more efficiently. However, these study designs are highly dependent on the research question(s) being asked, so prior to embarking on a new study, we suggest getting in touch with our experts in combination drug study design to ensure your study is optimized for success. We can support you with novel combination strategies, to optimize your research and enhance cancer treatment outcomes. Discover the power of combination therapies: https://hubs.la/Q02Yxt2b0

As #CancerImmunotherapyMonth comes to a close, we remain committed to discovering new approaches to cancer immunotherapy that open the door to potential novel treatments for patients in need. At Arcus, we have focused on building exceptional small molecule, medicinal chemistry and antibody capabilities to optimize the combinability of molecules within our portfolio. Learn from our President Juan Jaen and CMO Dimitry Nuyten about how we are targeting the #adenosineaxis to harness the body’s own immune system to attack and destroy #coloncancer: https://bit.ly/3VbWzJg

Want to understand the crucial role of biomarker discovery in breast cancer subtyping? Join us for an educational webinar on: ‘Streamlining Biomarker Discovery: From Theory to Application’ 👨💻 Who: Marko Tumbas and Svetozar Nesic 📅 When: Thursday 11th April 14:00-15:00 (BST) 💻 How: sign up to receive access👀:https://lnkd.in/ep9K6gev Want to learn more? Book a meeting with us to discuss 👉 https://lnkd.in/enZAjPfG #Webinar #BioX #Bioinformatics #BiomarkerDiscovery #BreastCancer 

A groundbreaking article on NuProbe's VarTrace qPCR assay for detecting Microsatellite Instability (MSI) in cancer using a novel tumor-only approach is featured in the Clinical Chemistry journal. We're especially proud that our Seraseq MSI Reference Panel played a crucial role, demonstrating a detection limit of 5% variant allele frequency and an input limit of 0.5 ng. Discover how this advancement is transforming cancer diagnostics and clinical workflows. Read the Article: https://hubs.ly/Q02FQR3w0 #CancerResearch #MSI #ClinicalChemistry #Seraseq

Ten years after the groundbreaking FDA approval of checkpoint inhibitors, immuno-oncology (IO) is on the cusp of a new era. In BioSpace, Mural CEO Caroline J Loew, PhD reflects on the challenges, advances, and promise of ‘IO 2.0’—a wave driven by nimble biotech companies like ours, bringing innovative therapies beyond PD-1 inhibitors aiming to transform cancer care. Read on to see why we’re excited about this next chapter in IO: https://lnkd.in/gXan3Nmb

Antibody-drug conjugates (ADCs) are transforming cancer therapy by precisely targeting and eliminating cancer cells while sparing healthy tissue. But have you ever wondered what makes this possible? Enter Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)—the unsung hero that deciphers the behavior of these breakthrough drugs within the body. Discover how LC-MS/MS is pioneering a new era of cancer care in our latest blog post. #CancerResearch #LCMS #ADCs #Biotechnology https://hubs.li/Q02GcGps0

Data that shows a linear trend are likely to have a strong association with PCs. Therefore, when you use PCA, the interpretation of the data is going to be highly accurate. For example, here in these plots, I separated ER+ and ER- breast cancer samples without labeling the data. However, if PCA fails in interpretation, then you need to find alternative methods which can give the best interpretation. #bioinformatics #PCA

As we make advances in immuno-oncology research, the length of the clinical trial to evaluate new drug efficacy can be significant. Dr Jeff Allen, Friends of Cancer Research, discusses efforts to evaluate ctDNA as an earlier potential endpoint for drug efficacy, and providing industry with a road map for future use in clinical trials. Read the interview here: https://lnkd.in/g2vruGVG #IO360Summit #immunooncology #ctDNA

A groundbreaking article on VarTrace qPCR assay for detecting Microsatellite Instability (MSI) in cancer using a novel tumor-only approach is featured in the Clinical Chemistry journal. We're especially proud that our Seraseq MSI Reference Panel played a crucial role, demonstrating a detection limit of 5% variant allele frequency and an input limit of 0.5 ng. Discover how this advancement is transforming cancer diagnostics and clinical workflows. Read the Article: https://hubs.ly/Q02FQQ4S0 #CancerResearch #MSI #ClinicalChemistry #Seraseq